8th Health & Care Webinar Online 10 November 2021


### Long COVID


Nicola Oliver, Longevity/mortality expert, Medical Intelligence, Co-chair C19-ARG Adrian Baskir, Chief Underwriting Officer, Bupa Insurance Ltd, C19-ARG member Josephine Robertson, FIA CERA MPH, C-19ARG member



- Long COVID
  - Definitions
  - Clinical Picture
  - Prevalence
  - Predictors
  - Impact











 Bone mineral thinning

#### Neuropsychiatric



- Fatigue
- Sleep disturbances
- Myalgia
- Headache
- Brain fog
- PTSD


### Haematologic






Thromboembolic events

#### Respiratory



- Pulmonary fibrosis
- Reduced pulmonary function


#### Renal



- Acute kidney injury
- Chronic kidney disease

#### Cardiovascular





- Myocarditis
- Myocardial fibrosis

÷,

#### **COVERSCAN** Study







Figure 2 Percentage of patients (black) and controls (grey) with individual organ measures outside of the predefined normal range. Lines represent significant difference in the proportions between the two groups, with \*p<0.05, \*\*p<0.01, \*\*\*p<0.001. LV, left ventricular.


Age-specific prevalence of self-reported long COVID, as a percentage of the population, according to resulting activity limitation, UK, 2 May 2021






Source: Office for National Statistics









Summary



The long tail of COVID is likely to be substantial

Multi-system damage

Future burden of morbidity and mortality

Additional impact of reduced access to other healthcare services

## Impact

- Population
- Societal






Long Covid: 'Is this now me for ever?' | Coronavirus | The Guardian



#### • Infections

#### Daily new confirmed COVID-19 cases

7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.



Source: Johns Hopkins University CSSE COVID-19 Data

www.actuariesindia.org

Our World in Data

https://ourworldindata.org




#### • Estimating disease burden

Positive Test			
Recovery	Hospitalised Ward		Home
Long COVID	Recovery	Hospitalised ITU	
Deceased <b>1 - Not admitted to hospital</b> <b>and surviving</b>	Long COVID Deceased	Recovery Long COVID	
	2. Admitted to hospital ward and surviving – excluding those who then move to ITU	Deceased	
		3. Admitted to hospital ITU and surviving– including those admitted to ward and transferred to ITU	

#### Possible pathways of care where long COVID can emerge



- Estimating disease burden
  - Estimating prevalence by symptoms



Symptom prevalence across studies identified in the UK by duration and severity groups

### Symptomatic Long COVID

- Group 2 & 3
- Hospitalised and Non

#### **COVID** injured

- Group 1
- Long tail of permanent injury
- Hospitalised



Estimating disease burden
– Estimating the QALY impact

Equation 1


$$\Delta Q_{COVID} = \sum_{\substack{Cohort = (symptomatic \ COVID, \\ COVID \ injured)}} \left( \sum_{t=0}^{t=time \ horizon} \frac{T_I * P_{Cohort,t} * (1 - U_{Cohort})}{365.25 * (1 + d)^{\frac{t}{365.25}}} \right)$$

Where:

- $\Delta Q_{COVID}$  is the number of lost QALYs across the population as a result of COVID infection;
- *t* is the day with respect to time zero;
- $T_I$  is the total number of people infected;
- *P<sub>Cohort,t</sub>* is the proportion of all infections that are symptomatic on day t;
- *U<sub>Cohort</sub>* is the change in utility based on the quality-of-life index for a person who is symptomatic in each cohort; and
- *d* is the annual discount rate.




• Estimating disease burden



Cumulative lost QALYs for symptomatic COVID and permanent injury due to COVID

Share of people vaccinated against COVID-19, Nov 5, 2021 Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries. Our World in Data

Share of people fully vaccinated against COVID-19 Share of people only partly vaccinated against COVID-19




Source: Official data collated by Our World in Data. This data is only available for countries which report the breakdown of doses administered by first and second doses in absolute numbers. CC BY

https://ourworldindata.org

# Societal Impact



• Intervention stages at each level of prevention



Reproduced from : Frank JW. Disease prevention : a critical toolkit. Jepson R, Williams AJ, editors. Oxford]: Oxford : Oxford University Press; 2016.

# Long COVID - Insurance Perspective

Acute COVID-19 Signs and symptoms of COVID-19 for up to 4 weeks


#### Long COVID

Ongoing symptomatic COVID-19 Signs and symptoms of COVID-19 from **4 to 12** weeks

Post COVID-19 syndrome Signs and symptoms that develop during or after an infection consistent with COVID-19, continue for **more than 12 weeks** and are <u>not explained by an</u> <u>alternative diagnosis</u>

- The chances of developing long COVID <u>does not seem to</u> <u>be linked to severity</u> of the acute COVID infection
- Difficult to determine numbers ... long COVID only recently started being recorded as a diagnosis in the UK and different studies use different definitions

As it is not understood what causes Long COVID there is not a diagnostic test for it; instead it is a diagnosis by exclusion. Similarly, treatment approach is determined by assessment and clinical judgement of the clinicians



## **Treatment – Public Sector**

#### National Health Service (NHS) - UK

- NHS 111 Assessing current COVID symptoms.
- NHS Primary Care GP
  - Still experiencing symptoms 4 weeks after a positive Covid-19 test, contact your GP.
  - Typically involve an initial consultation to understand symptoms and their impact.
  - Could result in a referral to the Long COVID specialist rehabilitation service
- Dedicated NHS COVID Recovery website
  - One-stop portal for all COVID recovery and self-help support.
  - For Long COVID, drives people to see their GP and from there to the Long COVID service

#### NHS Long COVID Rehabilitation Services

- Available by GP referral only if still experiencing symptoms of COVID-19 beyond 12 weeks.
- Appointments available virtually and face to face.
- Patients undergo a number of physical, cognitive and psychological assessments.
- Support plan to improve health outcomes / quality of life.
- Signposted to existing Long COVID support services and will have access to the 'Living with COVID' App, offering patients education, support and encouragement.
- 90 Clinics today in England


## Treatment – Private Sector



	Private sector - UK	
Initial consultation	• <b>Private GPs.</b> An emerging number of private providers marketing long COVID consultation, investigation and tailored treatment services	
General tests and investigations	<ul> <li>Hospital A. Long COVID Clinic offers consultation, diagnostics tests and referrals to appropriate services</li> <li>Hospital Group B offers a Post COVID Recovery Service; consultation, range of diagnostic tests plus referral to physio rehab service</li> </ul>	
Specialist investigation	Standard private provision	
Self management	n/a	
Rehabilitation	<ul> <li>Clinic Network C – offering 12 week rehab programme triaged online by a Nuffield Physio. Access to rehab specialist virtually with home exercises, then referral to Nuffield gym. Plus weekly emotional support calls.</li> <li>Hospital Group D (Birmingham) - marketing tailored, consultant-led rehabilitation programmes</li> </ul>	
Management of acute condition	Standard private provision	

# Paying for Long COVID

Diagnosis, treatment and management



# How Many People Are Affected?

- Some NHS sources state 20-30% have at least one ongoing symptoms by 4 weeks and 10% by 12 weeks
- A study by **Imperial College** reported in June 2021 found c.**6%** of study participants reporting at least one of 29 symptoms linked with COVID-19 for 12 weeks or more
  - A rapid drop off in proportion of people with symptoms was observed after four weeks, with a smaller drop by 12 weeks. Little change was seen in proportion of people experiencing symptoms between 3 months and 5 months
     October, the ONS reported an estimated 1.1 million people living in the LIK were

Insurers

- In October, the ONS reported an estimated 1.1 million people living in the UK were experiencing self-reported long COVID symptoms
  - 77% (831,000) had been experiencing their symptoms for at least 12 weeks, and 37% (405,000) had been experiencing the symptoms for at least a year
- Potential difference in exposure between insured and general populations assumed to be lower in insured due to socio-demographic factors
- Exposure does not always translate into costs due to self-management or failure to seek further treatment

**Consider Underwriting** 


**Implications of Vaccines?** 

 Kings College London study ... vaccination can half the chance of someone with acute COVID developing long COVID

## **Insurance Policy Implications**

This will vary from insurer to insurer but some general thoughts:

- There may be a pandemic exclusion
- Complications arising following COVID are typically eligible unless specifically excluded or covered by pandemic exclusion
- Coverage for all **acute condition/symptoms**, subject to the insurer's rules around **referral** (eg may require **pre-authorisation**) and the referral specifically requires **secondary care**.
- Claims risk exposure along the claims pathway whilst alternative, eligible diagnoses are being ruled out, and for treatment of acute conditions.
- After a Long COVID diagnosis the expected treatment and monitoring may not be eligible
- Typically higher frequency, low severity events



# **Underwriting Considerations**

#### Ask the question – Do you suffer from Long COVID? IF YES, then Exclude or Load

#### BUT ...

- Chance that treatment for long COVID remains undiagnosed especially for those that were asymptomatic
- Difficulty of predicting who will be at future risk for long COVID
- In the absence of a Long COVID diagnosis, high prevalence of ("short") COVID in population makes full exclusion unrealistic for most insurers unless after a market niche as it will exclude too big a market
- Understanding of COVID-19, it's long-term consequences, and best practice for diagnosing and managing these is still evolving making it difficult to predict long term exposure
- If Long COVID were to be excluded:
  - It is very challenging to identify if a claim is related to a complication of COVID or other condition.
  - Even if the long-term effects were excluded, additional costs may still be incurred by consultations/ diagnostics until the root cause of the symptom is established
- A number of **private providers are marketing long COVID packages** which risks driving private demand ... however, conversely this would **make claim identification easier**

#### Given the high frequency / low severity nature ... and data challenges ... COMMUNITY RATE THE IMPACT



